Naval G. Daver

Magrolimab in Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes: 5F9005 Phase 1b Study Results

Introduction:

Deepa Jeyakumar ;

Eunice S. Wang ;

Joshua F. Zeidner ;

David A. Sallman ;

Daniel A. Pollyea , MD, MS;

Guillermo Garcia-Manero , MD;

Naval G. Daver ;

Joseph G. Jurcic ;

Suman N. Kambhampati ;

Monzr M. Al Malki ;

Tiffany N. Tanaka ;

Terrence J. Bradley ;

11/04/2022

A Phase 3, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (ENHANCE-3)

Introduction:

Naval G. Daver ;

Giri Ramsingh ;

Scott Werneke ;

Evelyn Rustia ;

11/04/2022

Tolerability and Efficacy of the First-in-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia: Phase 1b Results

Introduction:

Joshua F. Zeidner ;

Suman N. Kambhampati ;

David A. Sallman ;

Monzr M. Al Malki ;

Richard Larson ;

Gabriel Mannis ;

Wanxing Chai-Ho ;

Tiffany N. Tanaka ;

Terrence J. Bradley ;

Deepa Jeyakumar ;

Eunice S. Wang ;

Giri Ramsingh ;

Camille Renard ;

Naval G. Daver ;

11/04/2022

A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia

Introduction:

Naval G. Daver ;

Giri Ramsingh ;

Camille Renard ;

David A. Sallman ;

Andrew H. Wei ;

11/04/2022

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

DCLF

March 17 ⁠–⁠ March 19

NP Institute

March 27 ⁠–⁠ March 30

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

April 30 ⁠–⁠ May 4

April 30 ⁠–⁠ May 5

WoundCon

May 1 ⁠–⁠ May 3

May 19 ⁠–⁠ May 21

See Full Calendar